Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 3168Uterine Cervical Neoplasms 2191Endometrial Neoplasms 1334Breast Neoplasms 819Fallopian Tube Neoplasms 808Carcinoma, Ovarian Epithelial 772Neoplasms 540Colorectal Neoplasms 439Carcinoma, Non-Small-Cell Lung 420Uterine Cervical Dysplasia 376Pancreatic Neoplasms 363Stomach Neoplasms 354Prostatic Neoplasms 318Lung Neoplasms 315Melanoma 289Uterine Neoplasms 239Peritoneal Neoplasms 238Neoplasm Metastasis 238Vulvar Neoplasms 229Urinary Bladder Neoplasms 225Esophageal Neoplasms 225Head and Neck Neoplasms 222Sarcoma 219Carcinoma, Renal Cell 214Recurrence 213Colonic Neoplasms 210Papillomavirus Infections 206Triple Negative Breast Neoplasms 191Squamous Cell Carcinoma of Head and Neck 177Vaginal Neoplasms 147

Interventions

adavosertib 1Paclitaxel 1Gemcitabine 1Carboplatin 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation × Gynecologic × Clear all
NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AstraZeneca

Phase 2 Completed
95 enrolled 61 charts
Gynecologic

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡